What is PNC-27?

Anti-cancer peptide, PNC-27, is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes of solid tissue tumor cells. The peptide induces transmembrane pore formation in cancer, but not in normal cells, resulting in tumor cell necrosis (cell death).

PNC-27 has shown to be highly effective in selectively targeting a wide variety of specific forms of cancer, including pancreatic cancer, breast cancer, leukemia, melanoma, and additional cancer lines.

How does PNC-27 work?

PNC-27 is a peptide compound designed to target cancer cells specifically. It works by disrupting the cell membrane of cancer cells, leading to their destruction through a process known as apoptosis, or programmed cell death. This disruption is thought to occur due to the peptide’s ability to interact with certain proteins or structures on the surface of cancer cells, triggering signaling pathways that ultimately result in cell death.

While laboratory studies have shown promising results regarding the anticancer effects of PNC-27 against certain types of cancer cells, its exact mechanism of action and its effectiveness in human cancer treatment are still being investigated. Further research, including clinical trials, is needed to fully understand how PNC-27 works and its potential as a cancer therapy.

Indications of PNC-27:

• Target cancer cells

Dose: 5 mg/vial
Dosing Guideline: 200-300 mcg 3 times/week